Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2015 | Pages:
62 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
H3N2 Infection - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'H3N2 Infection - Pipeline Review, H1 2015', provides an overview of the H3N2 Infection's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for H3N2 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H3N2 Infection and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of H3N2 Infection - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for H3N2 Infection and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the H3N2 Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the H3N2 Infection pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for H3N2 Infection - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding H3N2 Infection pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of table 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 H3N2 Infection Overview 7 Therapeutics Development 8 Pipeline Products for H3N2 Infection - Overview 8 Pipeline Products for H3N2 Infection - Comparative Analysis 9 H3N2 Infection - Therapeutics under Development by Companies 10 H3N2 Infection - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 H3N2 Infection - Products under Development by Companies 14 H3N2 Infection - Companies Involved in Therapeutics Development 15 AlphaVax, Inc. 15 Colby Pharmaceutical Company 16 Crucell N.V. 17 Cure Lab, Inc. 18 Inovio Pharmaceuticals, Inc. 19 Johnson & Johnson 20 NanoViricides, Inc. 21 REPLICor Inc. 22 Takeda Pharmaceutical Company Limited 23 Vaxart, Inc. 24 H3N2 Infection - Therapeutics Assessment 25 Assessment by Monotherapy Products 25 Assessment by Combination Products 26 Assessment by Target 27 Assessment by Mechanism of Action 29 Assessment by Route of Administration 31 Assessment by Molecule Type 33 Drug Profiles 35 Aspidasept - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 AVX-502 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 bordetella pertussis [strain BPZE1] vaccine - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 C-05 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 CLVax-1.0 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 CR-9114 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Gamma-Flu - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 ID-38 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 influenza [H3N2] vaccine - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 influenza vaccine - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 JVRS-100 + influenza [H1N1/H3N2] vaccine - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 NVINF-1 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 NVINF-2 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 REP-9 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 seasonal influenza [H3N2] vaccine - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 VX-787 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 H3N2 Infection - Recent Pipeline Updates 53 H3N2 Infection - Dormant Projects 59 H3N2 Infection - Product Development Milestones 60 Featured News & Press Releases 60 Oct 09, 2012: NanoViricides's Oral FluCide Drug Candidate Found To Be Superior To Oseltamivir In Reduction Of Virus Load And Lung Damage Pathology In Animal Models With H3N2 Influenza 60 Appendix 61 Methodology 61 Coverage 61 Secondary Research 61 Primary Research 61 Expert Panel Validation 61 Contact Us 61 Disclaimer 62
List of Tables Number of Products under Development for H3N2 Infection, H1 2015 8 Number of Products under Development for H3N2 Infection - Comparative Analysis, H1 2015 9 Number of Products under Development by Companies, H1 2015 11 Comparative Analysis by Clinical Stage Development, H1 2015 12 Comparative Analysis by Early Stage Development, H1 2015 13 Products under Development by Companies, H1 2015 14 H3N2 Infection - Pipeline by AlphaVax, Inc., H1 2015 15 H3N2 Infection - Pipeline by Colby Pharmaceutical Company, H1 2015 16 H3N2 Infection - Pipeline by Crucell N.V., H1 2015 17 H3N2 Infection - Pipeline by Cure Lab, Inc., H1 2015 18 H3N2 Infection - Pipeline by Inovio Pharmaceuticals, Inc., H1 2015 19 H3N2 Infection - Pipeline by Johnson & Johnson, H1 2015 20 H3N2 Infection - Pipeline by NanoViricides, Inc., H1 2015 21 H3N2 Infection - Pipeline by REPLICor Inc., H1 2015 22 H3N2 Infection - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 23 H3N2 Infection - Pipeline by Vaxart, Inc., H1 2015 24 Assessment by Monotherapy Products, H1 2015 25 Assessment by Combination Products, H1 2015 26 Number of Products by Stage and Target, H1 2015 28 Number of Products by Stage and Mechanism of Action, H1 2015 30 Number of Products by Stage and Route of Administration, H1 2015 32 Number of Products by Stage and Molecule Type, H1 2015 34 H3N2 Infection Therapeutics - Recent Pipeline Updates, H1 2015 53 H3N2 Infection - Dormant Projects, H1 2015 59
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
